Shots:

• Editas to receive $70M up front- milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies
• In May’2015- Editas and Juno entered into an exclusive collaboration to develop CAR T and TCR Cell Therapies- under which Editas has received $25M as upfront & ~$22M to support research over the next five years across the three programs in the alliance along with $230M research- regulatory- and commercial milestones and royalties for each program
• The amended agreement replaces the original agreement- allowing Editas to develop non-alpha-beta T cell therapies while expanding Celgene’s access to gene-edited alpha-beta T cells beyond oncology

Click here to­ read full press release/ article | Ref: Editas  | Image: The Boston Globe